1988
On the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemissionHodgkin's Disease Therapeutic Program
DeVita V. Hodgkin's Disease Therapeutic Program. JAMA 1972, 222: 1171-1171. PMID: 4678060, DOI: 10.1001/jama.1972.03210090051025.Peer-Reviewed Original ResearchConceptsCombination of drugsRemission durationHodgkin's diseaseCombinations of effective drugsProlongation of remission durationAdvanced Hodgkin's diseaseComplete remission rateAcute childhood leukemiaRemission rateProcarbazine hydrochlorideRate of inductionCooperative trialsEffective drugsChildhood leukemiaRemissionTherapyDrugPilot studyDiseaseHodgkinDurationMOPPProcarbazineMethotrexateLeukemia